IP Library › Granted Patent US 12,201,655
Granted Patent B2
US 12,201,655 · App. 17/220,308 · Granted Jan 21, 2025

Antimicrobial therapy

Inventors: Teruaki Nakatsuji (San Diego, CA); Richard L. Gallo (San Diego, CA)
Assignee: The Regents of the University of California
A61K35/741A61K9/0014A61K9/06A61K9/14A61K35/744A61K38/164A61K38/1729A61P17/00A61P31/04C07K14/31A61K2035/115
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,201,655
App. No.
17/220,308
Granted
Jan 21, 2025
Kind
B2
Abstract

Methods and compositions comprising hogocidin peptides (SH-lantibiotics), derivatives and variants are provided. Also provided are methods and compositions comprising probiotic compositions utilizing strains of S. hominis and S. epidermidis that produce hogocidin, hogocidin-like peptides, or other inhibitors of skin pathogens. Methods of treatment for microbial skin infections and atopic dermatitis are also provided.

Claims (23)

1. A method of treating a skin disease or disorder, comprising:

contacting a subject having a skin disease or disorder with an effective amount of a composition comprising:

a peptide comprising the sequence of KCSWWNASCHLGNNGKICTVSHECAAGCNL (SEQ ID NO: 56) or ATPTITTSSATCGGIIVAASAAQCPTLACSSRCGKRKK (SEQ ID NO: 57); and

one or more pharmaceutical excipients.

2. The method of claim 1 , wherein the composition comprises one or more probiotic bacteria capable of producing the peptide.

3. The method of claim 2 , wherein the one or more probiotic bacteria comprises one or more coagulase-negative bacterial strains of the genus Staphylococcus.

4. The method of claim 1 , wherein the skin disease or disorder is a skin infection, a skin colonization, a mucosal infection, a mucosal colonization, or any combination thereof.

5. The method of claim 1 , wherein the skin disease or disorder is folliculitis, atopic dermatitis, psoriasis, mastitis, acne, or any combination thereof.

6. The method of claim 1 , wherein the composition comprises a prebiotic compound, a protectant, humectant, emollient, abrasive, salt, a surfactant, or any combination thereof.

7. The method of claim 1 , wherein the composition is a topical formulation.

8. The method of claim 1 , wherein the skin disease or disorder comprises Staphylococcus aureus infection.

9. The method of claim 1 , wherein the peptide is post-translationally modified.

10. The method of claim 2 , wherein the one or more probiotic bacteria strains are provided in a live form.

11. The method of claim 2 , wherein the one or more probiotic bacteria strains are provided in a lyophilized form, a freeze-dried form, a spray dried form, or a mixture thereof.

12. The method of claim 11 , wherein the one or more probiotic bacteria strains can be reconstituted into a live form.

13. The method of claim 2 , wherein the one or more probiotic bacteria strains are present in said composition at a concentration of at least 10 3 CFU/gram.

14. The method of claim 1 , wherein the composition further comprises a cathelicidin peptide.

15. The method of claim 1 , wherein the peptide comprises one or more D-amino acids.

16. The method of claim 1 , wherein the peptide comprises one or more non-naturally occurring amino acids.

17. The method of claim 1 , wherein the subject is a mammal.

18. The method of claim 17 , wherein the subject is a human.

19. The method of claim 1 , wherein the composition is applied topically.

20. The method of claim 1 , wherein the composition is the form of a cream, ointment, unguent, spray, powder, oil, thickened formulation or poultice.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 21, 2021
From: GALLO, RICHARD L.; NAKATSUJI, TERUAKI
To: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Reel/Frame 055986/0896 →
Continuity (5)
Continuation 16653911 · Oct 15, 2019
Division 15570272
Provisional Application 62157248 · May 5, 2015
Provisional Application 62300274 · Feb 26, 2016
Related Publication 20210228652A1 · Jul 29, 2021
References Cited (31)
US 5925556A · Tokiwa et al. · 1999 [cited by applicant]
US 10980848B2 · Nakatsuji · 2021 [cited by examiner]
US 20080026999A1 · Van Der Donk et al. · 2008 [cited by applicant]
US 20090041727A1 · Suzuki et al. · 2009 [cited by applicant]
US 20090305260A1 · Kuribayashi et al. · 2009 [cited by applicant]
US 20100166708A1 · Gallo et al. · 2010 [cited by applicant]
US 20150050253A1 · Gabant · 2015 [cited by applicant]
WO 2011125015A2 · 2011 [cited by applicant]
WO 2012112548A2 · 2012 [cited by applicant]
Christensen et al., Bacterial skin commensals and their role as host guardians. Beneficial Microbes, 2014, vol. 5(2): 201-215. (Year : 2014). [cited by examiner]
Genchi G., An overview on D-amino acids. Amino Acids, 2017, vol. 49:1521-1533. (Year: 2017). [cited by examiner]
Williams et al., Quorum sensing between bacterial species on the skin protects against epidermal injury in atopic dermatitis. Sci. Transl. Med. 11, eaat8329, 2019, pp. 1-12. (Year: 2019). [cited by examiner]
Excipient, 4 pages downloaded from https://en.wikipedia.org on Apr. 13, 2023 (Year: 2023). [cited by examiner]
Nagaoka et al., Therapeutic Potential of Cathelicidin Peptide LL-37, an Antimicrobial Agent, in a Murine Sepsis Model. Int. J. Mol. Sci., 2020, vol. 21, 5973, pp. 1-16. (Year: 2020). [cited by examiner]
Murakami et al., Cathelicidin Anti-Microbial Peptide Expression in Sweat, an Innate Defense System for the Skin. The Soc, Invest. Dermatology., 2002, vol. 119(5): 1090-1095. (Year: 2002). [cited by examiner]
Travis et al., Bactericidal Activity of Mammalian Cathelicidin-Derived Peptides. Infn. Immun., 2000, vol. 68(5): 2748-2755. (Year: 2000). [cited by examiner]
Zaiou et al., Antimicrobial and Protease Inhibitory Functions of the Human Cathelicidin (hCAP18/LL-37) Prosequence. The Soc, Invest. Dermatology., 2003, vol. 120(5): 810-816. (Year: 2003). [cited by examiner]
Hasegawa, Akane, Office Action, Patent Application No. 2017-557323, Japanese Patent Office, Feb. 16, 2021. [cited by applicant]
Mendoza-Olazaran et al., “Microbiological and Molecular Characterization of [cited by applicant]
Thomas, Shane, International Search Report and Written Opinion, PCT/US16/31067, Oct. 20, 2016. [cited by applicant]
Baharlou, International Preliminary Report on Patentability and Written Opinion, PCT/US2016/031067, The International Bureau of WIPO, Nov. 16, 2017. [cited by applicant]
Cogen, Anna L. et al., “Selective Antimicrobial Action is Provided by Phenol-Soluble Modulins Derived from [cited by applicant]
Gallo, Richard L. et al., “Microbial Symbiosis with the Innate Immune Defense System of the Skin”, Journal of Investigative Dermatology, vol. 131, No. 10, Oct. 1, 2011, pp. 1974-1980. [cited by applicant]
Higaki et al., “Distrubution and Antimicrobial Susceptability of Coagulase-negative [cited by applicant]
Kloos et al., “Update on Clinical Significance of Coagulase-Negative [cited by applicant]
Nakatsuji et al., “Dermatological Therapy by Topical Application of Non-Pathogenic Bacteria”, Journal of Investigative Dermatology, vol. 134, No. 1, Jan. 1, 2014, pp. 11-14. [cited by applicant]
Winger, Rudolf, Extended European Search Report, European Patent Office, Application No. 16790119.8, Dec. 20, 2018. [cited by applicant]
Islam et al., “Antimicrobial mechanism of lantibiotics”, Biochem. Soc. Trans., Dec. 2012, 1:40(6):1528-33. [cited by applicant]
Ogawa, Tomohiro, Office Action, Patent Application No. 2021-187890, Japanese Patent Office, Nov. 22, 2022. [cited by applicant]
Nakano, Ai, Office Action, Japan Patent Office, Application No. 2023-144981, Aug. 20, 2024. [cited by applicant]
Power et al., “A Naturally Occurring Novel Allele of Escherichia coli Outer Membrane Protein A Reduces Sensitivity to Bacteriophage”, Applied and Environmental Microbiology, Dec. 2006, pp. 7930-7932. [cited by applicant]